Discover 1,443 paid clinical trials in St. Petersburg, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,443
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
for
HER2-positive Breast Cancer, Breast Cancer
Location: Lakeland FL, Fort Lauderdale FL, Charlotte NC,
Sponsor: Jazz Pharmaceuticals
Sex: All
Age: 18+
Code: NCT07102381
Phase2, Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Location: Englewood FL, Lady Lake FL, Saint Augustine FL,
Sponsor: GlaxoSmithKline
Sex: All
Age: 18+
Code: NCT06679101
Phase3, Recruiting
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
for
Locally Advanced Pancreatic Adenocarcinoma,
Location: Lakeland FL, Atlanta GA, Decatur GA, Johns Creek GA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06998940
Phase3, Recruiting
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
for
Anatomic Stage II Breast Cancer AJCC v8,
Location: Lakeland FL, West Columbia SC, New Orleans LA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT07391774
Phase3, Recruiting
A Prospective Evaluation of the Catheter Science M3 "Mini Catheter" for Patients With Prostatic
for
Urinary Retention
Location: Lakeland FL
Sponsor: Dr. Gaines W. Hammond Jr. MD FACS
Sex: Male
Age: 50+
Code: NCT03339076
Recruiting
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC